The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise

Trial Profile

The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise

Suspended
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs GSK 2586881 (Primary)
  • Indications Acute lung injury; Respiratory distress syndrome
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 28 Feb 2018 to 14 Jul 2018.
    • 01 Dec 2017 Planned primary completion date changed from 21 Dec 2017 to 28 Feb 2018.
    • 01 Dec 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top